Abstract
Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells. In the past decade they have demonstrated potential as cancer therapeutics. These molecules contain a toxin, natural or usually derivatized, connected to a cancerhoming module, such as a monoclonal antibody or growth factor or their derivatives. Various cancer-homing toxins have been designed and tested in cell-lines, animalmodels and clinical trials. We review some of these data and discuss ways to better design cancer-homing toxins in the light of advances in cancer genomics, antibodyengineering techniques and computational algorithms.
Keywords: Downregulation, Toxins, Targeted-therapy, Cancer, Vascular-leak syndrome, Drug- design, Super-antigen, Clinicaltrials
Current Pharmaceutical Design
Title: Cancer-Homing Toxins
Volume: 8 Issue: 22
Author(s): H. C. Ng and H. E. Khoo
Affiliation:
Keywords: Downregulation, Toxins, Targeted-therapy, Cancer, Vascular-leak syndrome, Drug- design, Super-antigen, Clinicaltrials
Abstract: Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells. In the past decade they have demonstrated potential as cancer therapeutics. These molecules contain a toxin, natural or usually derivatized, connected to a cancerhoming module, such as a monoclonal antibody or growth factor or their derivatives. Various cancer-homing toxins have been designed and tested in cell-lines, animalmodels and clinical trials. We review some of these data and discuss ways to better design cancer-homing toxins in the light of advances in cancer genomics, antibodyengineering techniques and computational algorithms.
Export Options
About this article
Cite this article as:
Ng C. H. and Khoo E. H., Cancer-Homing Toxins, Current Pharmaceutical Design 2002; 8 (22) . https://dx.doi.org/10.2174/1381612023393477
DOI https://dx.doi.org/10.2174/1381612023393477 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Apoptotic Signaling in Pancreatic Cancer – Therapeutic Application (Supplemental Data)
Current Cancer Therapy Reviews TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Antiangiogenic Therapy
Current Pharmaceutical Design HIF-1 Signaling in Drug Resistance to Chemotherapy
Current Medicinal Chemistry Novel Benzimidazole Derivatives: Cytotoxic and Apoptotic Properties on Lung Cancer Cell Line
Letters in Drug Design & Discovery Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Indoles and Related Compounds as Cannabinoid Ligands
Mini-Reviews in Medicinal Chemistry ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets The Anti-hypoxia Potentials of Trans-sodium Crocetinate in Hypoxiarelated Diseases: A Review
Current Radiopharmaceuticals Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry